Confidential Treatment. The parties hereto understand that any information or recommendation supplied by the Sub-Adviser in connection with the performance of its obligations hereunder is to be regarded as confidential and for use only by the Investment Manager, the Company or such persons the Investment Manager may designate in connection with the Fund. The parties also understand that any information supplied to the Sub-Adviser in connection with the performance of its obligations hereunder, particularly, but not limited to, any list of securities which may not be bought or sold for the Fund, is to be regarded as confidential and for use only by the Sub-Adviser in connection with its obligation to provide investment advice and other services to the Fund.
Confidential Treatment. Customer understands that certain commercial and financial information contained in this Letter Agreement are considered by Boeing as confidential. Customer agrees that it will treat this Letter Agreement and the information contained herein as confidential and will not, without the prior written consent of Boeing, disclose this Letter Agreement or any information contained herein to any other person or entity.
Confidential Treatment. All information and advice furnished by one party to the other party (including their respective agents, employees and representatives and the agents, employees, and representatives of any affiliates) hereunder shall be treated as confidential and shall not be disclosed to third parties, except as may be necessary to comply with applicable laws, rules and regulations, subpoenas, court orders, and as required in the administration and management of the Funds. It is understood that any information or recommendation supplied or produced by Sub-Adviser in connection with the performance of its obligations hereunder is to be regarded as confidential and for use only by the Adviser and the Trust. Without limiting the foregoing, the Adviser and the Trust will only disclose portfolio information in accordance with the Trust’s portfolio information policy as adopted by the Board of Trustees.
Confidential Treatment. Customer understands that Boeing considers certain commercial and financial information contained in this Letter Agreement as confidential. Each of Customer and Boeing agree that it will treat this Letter Agreement and the information contained herein as confidential. Customer agrees to limit the disclosure of the contents of this Letter Agreement to employees of Customer with a need to know and who understand that they are not to disclose its content to any other person or entity without the prior written consent of Boeing. Notwithstanding the forgoing, Customer may disclose this Letter Agreement and the terms and conditions herein to its parent company, FedEx Corporation, to the Board of Directors of its parent corporation, FedEx Corporation, to its professional advisors under a duty of confidentiality with respect hereto, and as required by law. * Blank spaces contained confidential information which has been filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. BOEING PROPRIETARY Very truly yours, THE BOEING COMPANY By /s/ XXXXXX X. XXXX Its Attorney-In-Fact ACCEPTED AND AGREED TO this Date: December 14, 2011 Federal Express Corporation By /s/ XXXXXXX X. XXXX Its Vice President * Blank spaces contained confidential information which has been filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. BOEING PROPRIETARY The Boeing Company X.X. Xxx 0000 Xxxxxxx, XX 00000-0000 FED-PA-03712-LA-1106207 Federal Express Corporation 0000 Xxxxx Xxxxx Xxxx Xxxxxxx, XX 00000 Subject: Special Matters for Firm Aircraft Reference: Purchase Agreement No. PA-3712 (Purchase Agreement) between The Boeing Company (Boeing) and Federal Express Corporation (Customer) relating to Model 767-3S2F aircraft (Aircraft) This letter agreement (Letter Agreement) amends and supplements the Purchase Agreement. All terms used but not defined in this Letter Agreement shall have the same meaning as in the Purchase Agreement. The credit memorandum provided for in this Letter Agreement will be applicable to the Aircraft identified in Table 1-A of the Purchase Agreement only.
Confidential Treatment. The information contained herein (Information) represents confidential information and has value precisely because it is not available generally or to other parties. Boeing and Customer will limit the disclosure of the Information to (i) such party’s employees with a need to know the Information for purposes of performance of its obligations stated herein and who understand and agree that they are not to disclose the Information to any other person or entity without the prior written consent of the other party hereto, (ii) Boeing or Customer's auditors, insurance brokers and attorneys (Professional Advisors) who have a need to know the Information in connection herewith and from whom such party has first obtained a written obligation to confidentiality and restricted use that is no less restrictive than the terms of this Article, or (iii) any other person or entity as may be required by applicable law or governmental regulations. Such party will be fully responsible to the other party for it’s Professional Advisors' compliance with such obligations. This article and the protection of the Information will survive the expiration, termination and/or cancellation of this Order or the completion of the services provided herein. *** Page 3 CSGTA Order # SWA-RE-1000838 Southwest Airlines Co. If the foregoing correctly sets forth your understanding of our agreement with respect to the matters set forth above, please indicate your acceptance and approval below on or before July 15, 2010. EXECUTED ON July 2nd, 0000 XXX XXXXXX XXXXXXX XXXXXXXXX XXXXXXXX XX. /s/ Isabelle Session /s/ Xxxxxxx Van de Ven Signature Signature Xxxxxxx Van de Ven Printed Name Printed Name EVP - COO Title Title *** Page 4 CSGTA Order # SWA-RE-1000838 Attachment 1 to Letter Agreement SWA-MISC-1001320 ***
Confidential Treatment. All information and advice furnished by one party to the other party (including their respective agents, employees and representatives) hereunder shall be treated as confidential and shall not be disclosed to third parties, except as may be necessary to comply with applicable laws, rules and regulations, subpoenas or court orders. It is understood that any information or recommendation supplied by, or produced by, Sub-Adviser in connection with the performance of its obligations hereunder is to be regarded as confidential and for use only by the Adviser and the Trust. Without limiting the foregoing, the Adviser and the Trust will only disclose portfolio information in accordance with the Trust’s portfolio information policy as adopted by the Board of Trustees.
Confidential Treatment. The information contained herein represents confidential business information and has value precisely because it is not available generally or to other parties. Each party will limit the disclosure of its contents to its employees with a need to know the contents for purposes of helping it perform its obligations under the Purchase Agreement and who understand they are not to disclose its contents to any other person or entity without the prior written consent of the other party. Notwithstanding the foregoing, either party may disclose this Letter Agreement (i) for the purpose of regulatory requirements, including without limitation registrations and filings pursuant thereto, or as otherwise required by law, provided that the disclosing party makes commercially reasonable efforts to notify the non-disclosing party in advance of such disclosure and considers in good faith all limitations on such disclosure requested by the non-disclosing party; (ii) for the purpose of disclosure to its auditors and its legal advisors on a need to know basis who themselves agree not to further disclose such information; and (iii) to the extent such information is publicly available other than as a result of the disclosure by or on behalf of such party. DAL-PA-02022-LA-1104484 August 24, 2011 Open Configuration Matters LA Page 2 BOEING PROPRIETARY [***] Confidential portions of the material have been omitted and filed separately with the Securities and Exchange Commission. Very truly yours, THE BOEING COMPANY By /s/ Xxxx Xxxxxxxxx Its Attorney-In-Fact ACCEPTED AND AGREED TO this Date: August 24, 2011 DELTA AIR LINES, INC. By: /s/ Xxxxxxxxx Xxxxxx Its: Vice President - Fleet Strategy & Transactions DAL-PA-02022-LA-1104484 August 24, 2011 Open Configuration Matters LA Page 3 BOEING PROPRIETARY [***] Confidential portions of the material have been omitted and filed separately with the Securities and Exchange Commission. The Boeing Company P.O. Box 3707 Seattle, WA 98124 2207 DAL-PA-2022-LA-1104485 Delta Air Lines, Inc. PO Box 20706 Atlanta GA 30320-6001 Subject: [***] Guarantees Reference: Purchase Agreement No. PA-2022 (Purchase Agreement) between The Boeing Company (Boeing) and Delta Air Lines, Inc. (Customer) relating to Model 737-732/-832/-932 aircraft. This letter agreement (Letter Agreement) amends and supplements the Purchase Agreement. All terms used but not defined in this Letter Agreement shall have the same meaning as in the Purchase Agreement.
Confidential Treatment. Customer and Boeing understand that certain commercial and financial information contained in this Letter Agreement are considered by Boeing and Customer as confidential. Customer and Boeing agree that each will treat this Letter Agreement and the information contained herein as confidential and will not, without the prior written consent of the other, disclose this Letter Agreement or any information contained herein to any other person or entity, except as provided in this Letter Agreement or in the Purchase Agreements. Very truly yours, THE BOEING COMPANY By Its Attorney-In-Fact ACCEPTED AND AGREED TO this Date: , 2008 AMERICAN AIRLINES, INC. By Its VP Corporate Development and Treasurer Attachment A: [CONFIDENTIAL PORTION OMITTED AND FILED SEPARATELY WITH THE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT]. Attachment B: [CONFIDENTIAL PORTION OMITTED AND FILED SEPARATELY WITH THE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT]. Attachment C: [CONFIDENTIAL PORTION OMITTED AND FILED SEPARATELY WITH THE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT]. Attachment D: [CONFIDENTIAL PORTION OMITTED AND FILED SEPARATELY WITH THE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT]. Attachment E: [CONFIDENTIAL PORTION OMITTED AND FILED SEPARATELY WITH THE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT]. P.A. Nos. 1977, 1978, 1979, 1980, and 3219 [CONFIDENTIAL PORTION OMITTED AND FILED SEPARATELY WITH THE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT]. BOEING PROPRIETARY Attachment A to 6-1162-AKP-072R2 Examples
Confidential Treatment. Customer and Boeing understand that certain commercial and financial information contained in this Letter Agreement are considered by Boeing and Customer as confidential and are subject to the terms and conditions set forth in Letter Agreement No. UCH-PA-03776-LA-1208234. Very truly yours, THE BOEING COMPANY By /s/ *** Its Attorney-in-Fact ACCEPTED AND AGREED TO this Date: July 12, 2012 United Continental Holdings, Inc. By /s/ Xxxxxx Xxxxxxxx Its Senior Vice President – Finance and Treasurer BOEING / UNITED CONTINENTAL HOLDINGS, INC. PROPRIETARY UCH-PA-03776-LA-1207644 Attachment A to Letter Agreement No. UCH-PA-03776-LA-1207644 737-9 Option Aircraft Delivery, Description, Price and Advance Payments Airframe Model/MTOW: 737-9 *** pounds Detail Specification: *** Engine Model/Thrust: CFM-LEAP-1B *** pounds Airframe Price Base Year/Escalation Formula: *** *** Airframe Price: $ *** Engine Price Base Year/Escalation Formula: *** *** Optional Features: $ *** Sub-Total of Airframe and Features: $ *** Airframe Escalation Data: Engine Price (Per Aircraft): $ *** Base Year Index (ECI): *** Aircraft Basic Price (Excluding BFE/SPE): $ *** Base Year Index (CPI): *** Buyer Furnished Equipment (BFE) Estimate: $ *** Seller Purchased Equipment (SPE) Estimate: $ *** Deposit per Aircraft: $ *** Delivery Date Number of Aircraft Escalation Factor (Airframe) Actual or Nominal Delivery Month* Escalation Estimate Adv Payment Base Price Per A/P Advance Payment Per Aircraft (Amts. Due/Mos. Prior to Delivery): *** *** *** *** *** *** *** *** $ *** $ *** $ *** $ *** $ *** *** *** *** *** $ *** $ *** $ *** $ *** $ *** *** *** *** *** $ *** $ *** $ *** $ *** $ *** *** *** *** *** $ *** $ *** $ *** $ *** $ *** *** *** *** *** $ *** $ *** $ *** $ *** $ *** *** *** *** *** $ *** $ *** $ *** $ *** $ *** *** *** *** *** $ *** $ *** $ *** $ *** $ *** *** *** *** *** $ *** $ *** $ *** $ *** $ *** *** *** *** *** $ *** $ *** $ *** $ *** $ *** *** *** *** *** $ *** $ *** $ *** $ *** $ *** *** *** *** *** $ *** $ *** $ *** $ *** $ *** *** *** *** *** $ *** $ *** $ *** $ *** $ *** *** *** *** *** $ *** $ *** $ *** $ *** $ *** *** *** *** *** $ *** $ *** $ *** $ *** $ *** *** *** *** *** $ *** $ *** $ *** $ *** $ *** *** *** *** *** $ *** $ *** $ *** $ *** $ *** Boeing / United Continental Holdings, Inc. Proprietary Attachment A to Letter Agreement No. UCH-PA-03776-LA-1207644 737-9 Option Aircraft Delivery, Description, Price and Advance Payments Delivery Date Number of Aircraft Escalation Factor...
Confidential Treatment. It is understood that any information or recommendation supplied by, or produced by, Sub-Adviser in connection with the performance of its obligations hereunder is to be regarded as confidential and for use only by the Adviser and the Trust. Furthermore, except as required by law (including, but not limited to semi-annual, annual or other filings made under the 0000 Xxx) or as agreed to by the Adviser and Sub-Adviser, the Adviser and Trust will not disclose any list of securities held by the Fund until it is either filed with the Securities & Exchange Commission or mailed out to shareholders, which filing or mailing shall not be made sooner than 30 days after quarter end in any manner whatsoever except as expressly authorized in this Agreement, except that the top 10 holdings may be disclosed 15 days after month end. In addition, at the end of each quarter, the Adviser may disclose to certain third party data or service providers to the Fund, who have entered into a confidentiality agreement with the Adviser, a list of securities purchased or sold by the Fund during the quarter.
